StudyThe lancet. Healthy longevitySep 2027
Seeley AE, van der Veen R, Wang A, Glogowska M, Hayward G, Williamson E, Sheppard JP.
Background In older patients (≥65 years), the evidence for continued statin prescription is scarce. Although statins are commonly discontinued in the context of advancing age or frailty, there is little evidence to guide decision making. Hence, we aimed to inv...
PreprintPreprintNov 2026
Murugadoss K, Venkatakrishnan A, Soundararajan V.
Semaglutide lowers cardiovascular events in adults with obesity, but whether it slows biological aging of the heart, and whether any such effect is explained by weight loss, is unknown. We developed and validated a hybrid convolutional and transformer deep lea...
StudyGeroScienceNov 2026
Ditchfield C, Macleod M, Price JMJ, Davis ET, Jones SW.
GLP-1 and GIP/GLP-1 receptor agonists produce substantial weight loss in clinical trials but significant loss of lean body mass is reported. Whether this reflects a direct pharmacological effect on skeletal muscle or an indirect consequence of caloric restrict...
StudyJournal of Alzheimer's disease : JADOct 2026
Kamihara T, Kato R, Morisaki A, Kaneko S, Omura T, Shimizu A.
BackgroundAlzheimer's disease (AD) currently lacks fundamental curative treatments. While epidemiological evidence increasingly links sodium-glucose cotransporter 2 (SGLT2) inhibitors to reduced AD risk, the underlying molecular mechanisms remain poorly unders...
StudyEndocrineOct 2026
Jain V, McCoy RG.
Purpose Sodium-glucose cotransporter-2 inhibitors (SGLT2i) carry Class I, Level A recommendations for type 2 diabetes (T2D), heart failure (HF), and chronic kidney disease (CKD) but remain underused outside T2D, with formulary restrictions commonly cited as a ...
StudyFrontiers in cardiovascular medicineOct 2026
Seri A, Yue B, Khawaja M, Tang WHW, Birnbaum Y, Lavie CJ, Virani SS, Strauss M, Krittanawong C.
Cardiovascular health is a key factor in human longevity, affecting not just lifespan but also the quality of aging. We synthesize evidence across four risk factor domains: genetic and epigenetic factors (APOE, FOXO3, telomere biology, epigenetic clocks); meta...